Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF) has announced that its Toronto clinic in the Forest Hill neighbourhood, the Neurology Centre of Toronto (NCT) by Numinus, is now offering ketamine-assisted therapy for patients with neurologic conditions.
The mental health care company said the new service will be led by a psychologist and follow Numinus' existing protocol for ketamine-assisted therapy, already in use in its other locations in Canada and the US, which includes sessions for medical screening, medicine dosing and therapy for integration.
“Our patients often face complex challenges, including comorbid neurologic and mental health disorders,” Numinus Wellness CEO Payton Nyquvest said in a statement.
READ: Numinus Wellness updates on integration of Novamind acquisition
“By offering these additional services, we can help alleviate their distress and improve their quality of life,” Nyquvest added.
Numinus noted a group of existing patients has been reviewed as candidates, with plans to provide treatment to more patients following evaluation of the initial cohort.
It added that the protocol will be modified to ensure it is appropriate for patients with neurologic conditions.
As well, the company said that in addition to ketamine-assisted therapy, NCT is expanding its capabilities to support applications for other psychedelic-assisted therapies through Health Canada's Special Access Program (SAP), a federal program through which patients with demonstrable need can apply for access to investigational medical treatments that are not yet available to the public, including therapies using psychedelics such as MDMA and psilocybin.
Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies.
Contact Sean at sean@proactiveinvestors.com